These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9519355)

  • 1. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
    Denis LJ; Keuppens F; Smith PH; Whelan P; de Moura JL; Newling D; Bono A; Sylvester R
    Eur Urol; 1998; 33(2):144-51. PubMed ID: 9519355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
    Denis LJ; Carnelro de Moura JL; Bono A; Sylvester R; Whelan P; Newling D; Depauw M
    Urology; 1993 Aug; 42(2):119-29; discussion 129-30. PubMed ID: 8367920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
    de Voogt HJ; Studer U; Schröder FH; Klijn JG; de Pauw M; Sylvester R
    Eur Urol; 1998; 33(2):152-8. PubMed ID: 9519356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
    Denis L; Smith PH; De Moura JL; Newling DW; Bono A; Keuppens F; Robinson M; Mahler C; Sylvester R; De Pauw M
    Eur Urol; 1990; 18 Suppl 3():34-40. PubMed ID: 2151274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
    Keuppens F; Denis L; Smith P; Carvalho AP; Newling D; Bond A; Sylvester R; De Pauw M; Vermeylen K; Ongena P
    Cancer; 1990 Sep; 66(5 Suppl):1045-57. PubMed ID: 2144206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
    Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
    Kirby R; Robertson C; Turkes A; Griffiths K; Denis LJ; Boyle P; Altwein J; Schröder F
    Prostate; 1999 Jul; 40(2):105-14. PubMed ID: 10386471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
    Iversen P; Suciu S; Sylvester R; Christensen I; Denis L
    Cancer; 1990 Sep; 66(5 Suppl):1067-73. PubMed ID: 2144208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group.
    Keuppens F; Whelan P; Carneiro de Moura JL; Newling D; Bono A; Denis L; Robinson M; Mahler C; Sylvester R; De Pauw M
    Cancer; 1993 Dec; 72(12 Suppl):3863-9. PubMed ID: 8252505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
    Iversen P; Christensen MG; Friis E; Hornbøl P; Hvidt V; Iversen HG; Klarskov P; Krarup T; Lund F; Mogensen P
    Cancer; 1990 Sep; 66(5 Suppl):1058-66. PubMed ID: 2144207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
    Rosendahl I; Kiebert GM; Curran D; Cole BF; Weeks JC; Denis LJ; Hall RR
    Prostate; 1999 Feb; 38(2):100-9. PubMed ID: 9973095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
    Boccardo F; Rubagotti A; Barichello M; Battaglia M; Carmignani G; Comeri G; Conti G; Cruciani G; Dammino S; Delliponti U; Ditonno P; Ferraris V; Lilliu S; Montefiore F; Portoghese F; Spano G
    J Clin Oncol; 1999 Jul; 17(7):2027-38. PubMed ID: 10561254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
    Tyrrell CJ; Altwein JE; Klippel F; Jurincic-Winkler C; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
    Eur Urol; 2000 Feb; 37(2):205-11. PubMed ID: 10705200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
    Dimopoulos MA; Kiamouris C; Gika D; Deliveliotis C; Giannopoulos A; Zervas A; Alamanis C; Constantinidis C; Koutsilieris M
    Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.
    Newling DW; Denis L; Vermeylen K
    Cancer; 1993 Dec; 72(12 Suppl):3793-8. PubMed ID: 8252492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.